124750-92-1 Usage
Description
2-BUTYL-4-CHLORO-1-[(2'-(1-H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL)METHYL]-1-H-IMIDAZOLE-5-CARBOXYLIC ACID is a complex organic compound with a unique molecular structure that features a biphenyltetrazole group attached to an imidazole ring. 2-BUTYL-4-CHLORO-1-[(2'-(1-H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL)METHYL]-1-H-IMIDAZOLE-5-CARBOXYLIC ACID is characterized by its light-yellow solid appearance and is a metabolite of Losartan, a medication used to treat hypertension and heart failure.
Uses
Used in Pharmaceutical Industry:
2-BUTYL-4-CHLORO-1-[(2'-(1-H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL)METHYL]-1-H-IMIDAZOLE-5-CARBOXYLIC ACID is used as a metabolite of Losartan for its physiological activity. As a potent AT1 antagonist, it contributes to the depressor response and vasodilation effects of the parent compound, Losartan. This makes it a valuable component in the development and study of antihypertensive and heart failure treatments.
Used in Research and Development:
In the field of pharmaceutical research and development, 2-BUTYL-4-CHLORO-1-[(2'-(1-H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL)METHYL]-1-H-IMIDAZOLE-5-CARBOXYLIC ACID serves as an important compound for understanding the metabolic pathways and effects of Losartan. Its study can lead to the discovery of new drug candidates and the optimization of existing treatments for cardiovascular diseases.
in vitro
e-3174 potently blocked the specific binding of [125i]-aii to vsmc isolated from rat aorta. e-3174 was able to dampen the platelet-derived growth factor-induced increase in cell dna synthesis and protein, which led to the blockade of the aii-induced increase in cell protein [1].
in vivo
rats were administrated e-3174 intravenously at a dose of l.0 mg/kg. after 6 hours, e-3174 markedly attenuated the cardiovascular effects of aii in rats. e-3174 induced a progressive fall in mean arterial pressure and a marked increase in renal flow only [2].
references
[1]. li, x. & widdop, r. angiotensin type i receptor antagonists cy-11974 and exp 3174 cause selective renal vasodilatation in conscious spontaneously hypertensive rats. clinical science, 1996; 91(2): 147-154. [2]. sachinidis, a., ko, y., weisser, p., zu bricbkwedde, m., dsing, r., & christian, r. et al. exp3174, a metabolite of losartan (mk954, dup753) is more potent than losartan in blocking the angiotensin ll-induced responses in vascular smooth muscle cells. journal of hypertension. 1993; 11(2): 155-162.
Check Digit Verification of cas no
The CAS Registry Mumber 124750-92-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,4,7,5 and 0 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 124750-92:
(8*1)+(7*2)+(6*4)+(5*7)+(4*5)+(3*0)+(2*9)+(1*2)=121
121 % 10 = 1
So 124750-92-1 is a valid CAS Registry Number.
124750-92-1Relevant articles and documents
Design, synthesis and antihypertensive evaluation of novel codrugs with combined angiotensin type 1 receptor antagonism and neprilysin inhibition
Mascarello, Alessandra,Azevedo, Hatylas,Ferreira Junior, Marcos Antonio,Ishikawa, Eloisa Eriko,Guimar?es, Cristiano Ruch Werneck
, (2021)
The multifactorial etiology of hypertension has promoted the research of blood pressure-lowering agents with multitarget actions to achieve better clinical outcomes. We describe here the discovery of novel dual-acting antihypertensive codrugs combining pharmacophores with angiotensin type 1 (AT1) receptor antagonism and neprilysin (NEP) inhibition. Specifically, the codrugs combine the AT1 antagonists losartan or its carboxylic acid active metabolite (E-3174) with selected monocarboxylic acid NEP inhibitors through a cleavable linker. The resulting codrugs exhibited high rates of in vitro conversion into the active molecules upon incubation with human/rat liver S9 fractions and in vivo conversion after oral administration in rodents. Moreover, the acute effects of one of the designed codrugs (3b) was confirmed at the doses of 10, 30 and 60 mg/kg p.o. in the spontaneous hypertensive rat (SHR) model, showing better antihypertensive response over 24 hours than the administration of an equivalent fixed-dose combination of 15 mg/kg of losartan and 14 mg/kg of the same NEP inhibitor used in 3b. The results demonstrate that the codrug approach is a plausible strategy to develop a single molecular entity with combined AT1 and NEP activities, aiming at achieving improved pharmacokinetics, efficacy and dosage convenience, as well as reduced drug-drug interaction for hypertension patients. In addition, the developability of the codrug should be comparable to the one of marketed AT1 antagonists, most of them prodrugs, but bearing only the AT1 pharmacophore.
MANUFACTURING METHOD OF LOSARTAN METABOLITE EXP-3174
-
Paragraph 0073-0075; 0082-0084, (2020/09/30)
The present invention provides a manufacturing method capable of manufacturing a losartan metabolite EXP-3174 with high purity and high yield using inexpensive starting materials and under mild reaction conditions. The losartan metabolite EXP-3174 is represented by chemical formula 5.
Preparing method for EXP-3174
-
Paragraph 0016, (2016/10/09)
The invention discloses a preparing method for EXP-3174. The preparing method is characterized in that losartan is used as a starting raw material and is prepared into EXP-3174 through two-step oxidation. The preparing method has the greatest advantages that a reaction is moderate, the number of side reactions is small, aftertreatment is simple, and EXP-3174 with the purity of 99.9% can be obtained without column chromatography isolation.